Retrophin questioned over pricing of kidney disease treatment Thiola by lawmakers
MLex Summary: The US Senate Special Committee on Aging has sent a letter to the CEO of Retrophin Pharmaceuticals, requesting information on the company's purchase and subsequent pricing of kidney disease treatment...To view the full article, register now.
Already a subscriber? Click here to view full article